M
Mobolaji Olurinde
Researcher at Harvard University
Publications - 5
Citations - 593
Mobolaji Olurinde is an academic researcher from Harvard University. The author has contributed to research in topics: Internal medicine & Psoriasis. The author has an hindex of 1, co-authored 1 publications receiving 547 citations.
Papers
More filters
Journal ArticleDOI
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association
Jianhua Sui,Wenhui Li,Akikazu Murakami,Azaibi Tamin,Leslie J. Matthews,Swee Kee Wong,Michael Moore,Aimee St. Clair Tallarico,Mobolaji Olurinde,Hyeryun Choe,Larry J. Anderson,William J. Bellini,Michael Farzan,Wayne A. Marasco +13 more
TL;DR: Data suggest that the 80R human monoclonal antibody may be a useful viral entry inhibitor for the emergency prophylaxis and treatment of SARS, and that the ACE2-binding site of S1 could be an attractive target for subunit vaccine and drug development.
Journal ArticleDOI
Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry
April W. Armstrong,Timothy Fitzgerald,Robert R. McLean,Amanda Teeple,Jonathan Uy,Mobolaji Olurinde,Katelyn Rowland,Lin Guo,Ying Shan,Kristina Callis Duffin +9 more
TL;DR: In this article , the interleukin-23 inhibitor guselkumab was associated with significantly improved disease severity and patient-reported outcome measures (PROMs) among patients with moderate-to-severe plaque psoriasis.
Journal ArticleDOI
Real-World Effectiveness of 9–12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
April W. Armstrong,Timothy Fitzgerald,Robert R. McLean,Amanda Teeple,Jonathan Uy,Mobolaji Olurinde,Katelyn Rowland,Lin Guo,Ying Shan,Kristina Callis Duffin +9 more
TL;DR: Guselkumab, an anti-interleukin-23 biologic therapy, has been shown to significantly reduce disease activity and improve patient-reported outcome measures (PROMs) among patients with moderate-to-severe plaque psoriasis in clinical trials as discussed by the authors .
Journal ArticleDOI
The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry
April W. Armstrong,Timothy Fitzgerald,Robert R. McLean,Amanda Teeple,Jonathan Uy,Mobolaji Olurinde,Katelyn Rowland,Lin Guo,Ying Shan,Kristina Callis Duffin +9 more
Journal ArticleDOI
Characteristics of New Biologic Users Among the Moderate-to-Severe Psoriasis Population—Retrospective Cohort Study Leveraging the Modernizing Medicine Data Services Database
Timothy Fitzgerald,Aimee M. Near,Hyunchung Ray Kim,Amanda Teeple,Mobolaji Olurinde,Katelyn Rowland +5 more
TL;DR: In this article , the authors describe patient characteristics and previous treatments in psoriasis patients newly treated with guselkumab, secukinumab or ixekizumab.